Dermata Therapeutics (DRMA) Other Accumulated Expenses (2020 - 2026)

Dermata Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $50901.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 72.98% year-over-year to $50901.0; the TTM figure through Mar 2026 stood at $50901.0 (down 72.98% YoY), while the FY2025 annual figure was $432.0, down 99.69% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $50901.0, up from $432.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.1 million in Q3 2024, with the low at $432.0 in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $442359.0 (2023), against an average of $449650.9.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses jumped 144.72% in 2024, then slumped 99.69% in 2025.
• Dermata Therapeutics' Other Accumulated Expenses stood at $425932.0 in 2022, then jumped by 77.87% to $757588.0 in 2023, then plunged by 81.82% to $137759.0 in 2024, then plunged by 99.69% to $432.0 in 2025, then soared by 11682.64% to $50901.0 in 2026.
• Business Quant data shows DRMA's Other Accumulated Expenses at $50901.0 in Q1 2026, $432.0 in Q4 2025, and $57317.0 in Q3 2025.